Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study - Summary - MDSpire

Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study

  • By

  • Vratko Himic

  • Morgan Leigh Johnson

  • Anshul Ratnaparkhi

  • Roxanne C. Mayrand

  • Jay Chandar

  • Vaidya Govindarajan

  • Daniel C. Kreatsoulas

  • Arman Jahangiri

  • Zachary C. Gersey

  • Daniel M. Aaronson

  • Ricardo J. Komotar

  • Micheal E. Ivan

  • Ashish H. Shah

  • June 5, 2026

  • 0 min

Share

Objective:

To compare outcomes in patients with butterfly glioma following biopsy versus laser interstitial thermal therapy (LITT), focusing on survival metrics, post-operative complications, neurological function, and length-of-stay metrics.

Approach:
    Key Findings:
    • Remove unsupported claims about survival benefits and immune activation.
    • Clarify that findings are based on existing literature rather than direct study results.
    Interpretation:

    Remove unsupported conclusions about the role of LITT.

    Limitations:
    • The study is retrospective and may be limited by selection bias.
    • Previous studies on LITT have small sample sizes and lack comparative data.
    Conclusion:

    Omit the conclusion suggesting a systematic comparison is warranted.

Original Source(s)

Butterfly gliomas: to biopsy or to ablate – a longitudinal cohort study

  • by Vratko Himic, Morgan Leigh Johnson, Anshul Ratnaparkhi, Roxanne C. Mayrand, Jay Chandar, Vaidya Govindarajan, Daniel C. Kreatsoulas, Arman Jahangiri, Zachary C. Gersey, Daniel M. Aaronson, Ricardo J. Komotar, Micheal E. Ivan, Ashish H. Shah

  • June 5, 2026

Related Content

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study

HuBIE: The human blood immunome encyclopedia of TCRs and BCRs in bloodstream infections and cancer

Development and validation of hypermethylated gene markers in cervical cytological samples for detecting endometrial cancer (EndoMethy-I trial)